Emerging blood-based biomarkers for detection of gastric cancer

World Journal of Gastroenterology

Volumn 21, Issue 41, 2015, Pages 11636-11653

  Kalnina, Zane ^a   Meistere, Irena ^a   Kikuste, Ilze ^b,c   Tolmanis, Ivars ^b   Zayakin, Pawel ^a   Line, Aija ^a  

^a LATVIAN BIOMEDICAL RESEARCH AND STUDY CENTRE   (Latvia)

^b Digestive Diseases Centre GASTRO   (Latvia)

^c UNIVERSITY OF LATVIA   (Latvia)

Author keywords

Autoantibodies; Biomarker; Cell free DNA; Cell free RNA; Extracellular vesicles; Gastric cancer; Liquid biopsy; Proteomics

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CELL FREE NUCLEIC ACID; CELL FREE RNA; DNA FRAGMENT; LONG UNTRANSLATED RNA; MICRORNA; NUCLEIC ACID; RNA; UNCLASSIFIED DRUG; DNA; TUMOR MARKER; TUMOR PROTEIN;

ARTICLE; CANCER CONTROL; CANCER DIAGNOSIS; CANCER SCREENING; CELL FREE SYSTEM; CIRCULATING TUMOR CELL; DNA METHYLATION; EXOSOME; GEL ELECTROPHORESIS; GENE AMPLIFICATION; HUMAN; MULTICENTER STUDY (TOPIC); NONHUMAN; PROTEIN BLOOD LEVEL; PROTEOMICS; STOMACH CANCER; BLOOD; CANCER STAGING; EARLY CANCER DIAGNOSIS; GENETICS; GENOMICS; METABOLISM; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR EMBOLISM;

AUTOANTIBODIES; BIOMARKERS, TUMOR; DNA, NEOPLASM; EARLY DETECTION OF CANCER; GENOMICS; HUMANS; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; PREDICTIVE VALUE OF TESTS; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RNA, NEOPLASM; STOMACH NEOPLASMS; TREATMENT OUTCOME;

EID: 84947224850     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i41.11636     Document Type: Article

References (160)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
3. Lauren P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. an attempt at a histoclinical classification. Acta Pathol Microbiol Scand 1965; 64: 31-49 [PMID: 14320675]
4. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975; 2: 58-60 [PMID: 49653]
5. Hishida A, Matsuo K, Goto Y, Hamajima N. Genetic predisposition to Helicobacter pylori-induced gastric precancerous conditions. World J Gastrointest Oncol 2010; 2: 369-379 [ PMID: 21160888]
6. Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clin Endosc 2014; 47: 478-489 [PMID: 25505712 DOI: 10.5946/ce.2014.47.6.478]
7. Oliveira C, Pinheiro H, Figueiredo J, Seruca R, Carneiro F. Familial gastric cancer: genetic susceptibility, pathology, and implications for management. Lancet Oncol 2015; 16: e60-e70 [PMID: 25638682 DOI: 10.1016/S1470-2045(14)71016-2]
8. Orditura M, Galizia G, Sforza V, Gambardella V, Fabozzi A, Laterza MM, Andreozzi F, Ventriglia J, Savastano B, Mabilia A, Lieto E , Ciardiello F, De Vita F. Treatment of gastric cancer. World J Gastroenterol 2014; 20: 1635-1649 [PMID: 24587643 DOI: 10.3748/wjg.v20.i7.1635]
9. Rosati G, Ferrara D, Manzione L. New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol 2009; 15: 2689-2692 [PMID: 19522017]
10. Yoshida K, Yamaguchi K, Okumura N, Osada S, Takahashi T, Tanaka Y, Tanabe K, Suzuki T. The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology 2011; 78: 343-352 [PMID: 2 2104206 DOI: 10.1159/000328197]
11. Leja M, You W, Camargo MC, Saito H. Implementation of gastric cancer screening-the global experience. Best Pract Res Clin Gastroenterol 2014; 28: 1093-1106 [PMID: 25439074 DOI: 10.1016/j.bpg.2014.09.005]
12. di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis 2008; 40: 523-530 [PMID: 18439884 DOI: 10.1016/j.dld.2008.02.028]
13. Dinis-Ribeiro M, Yamaki G, Miki K, Costa-Pereira A, Matsukawa M, Kurihara M. Meta-Analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gas tritis screening. J Med Screen 2004; 11: 141-147 [PMID: 15333273]
14. Leja M,Kupcinskas L,Funka K,Sudraba A,Jonaitis L,Ivanauskas A,Janciauskas D,Kiudelis G,Chiu HM,Lin JT. The validity of a biomarker method for indirect detection of gastric mucosal atrophy versus standard hi stopathology Dig Dis Sci 2009 54 2377-2384 PMID: 19731026 DOI: 10.1007/s10620-009-0947-5]
15. Kikuchi S, Kato M, Katsuyama T, Tominaga S, Asaka M. Design and planned analyse s of an ongoing randomized trial assessing the preventive effect of Helicobacter pylori eradication on occurrence of new gastric carcinomas after endoscopic resection. Helicobacter 2006; 11: 147-151 [PMID: 16684261 DOI: 10.1111/j.1523-5378.2006.00392.x]
16. Kitahara F, Kobayashi K, Sato T, Kojima Y, Araki T, Fujino MA. Accuracy of screening for gastric cancer using serum pepsinogen concentrations. Gut 1999; 44: 693-697 [PMID: 10205207]
17. Kang JM, Kim N, Yoo JY, Park YS, Lee DH, Kim HY, Lee HS, Choe G, Kim JS, Jung HC, Song IS. The role of serum pepsinogen and gastrin test for the de tection of gastric cancer in Korea. Helicobacter 2008; 13: 146-156 [PMID: 18321304 DOI: 10.1111/j.1523-5378.2008.00592.x]
18. Yanaoka K, Oka M, Mukoubayashi C, Yoshimura N, Enomoto S, Iguchi M, Magari H, Utsunomiya H, Tamai H, Arii K, Ohata H, Fujishiro M, Takeshita T, Mohara O, Ichinose M. Cancer highrisk subjects identified by serum pepsinogen tests: outcomes after 10-year follow-up in asymptomatic middle-Aged males. Cancer Epidemiol Biomarkers Prev 2008; 17: 838-845 [PMID: 18398025 DOI: 10.1158/1055-9965.EPI-07-2762]
19. Mizuno S, Kobayashi M, Tomita S, Miki I, Masuda A, Onoyama M, Habu Y, Inokuchi H, Watanabe Y. Validation of the pepsinogen test method for gastric cancer screening using a follow-up study. Gastri c Cancer 2009; 12: 158-163 [PMID: 19890696 DOI: 10.1007/s10120-009-0522-y]
20. Herrero R, Park JY, Forman D. The fight against gastric cancer-the IARC Working Group report. Best Pract Res Clin Gastroenterol 2014; 28: 1107-1114 [PMID: 25439075 DOI: 10.1016/j.bpg.2014.10.003]
21. Liu W, Yang Q, Liu B, Zhu Z. Serum proteomics for gastric cancer. Clin Chim Acta 2014; 431: 179-184 [PMID: 24525212 DOI: 10.1016/j.cca.2014.02.001]
22. Omenn GS. THE HUPO Human Plasma Proteome Project. Proteomics Clin Appl 2007; 1: 769-779 [PMID: 21136733 DOI: 10.1002/prca.200700369]
23. Lin LL, Huang HC, Juan HF. Discovery of biomarkers for gastric cancer: a proteomics approach. J Proteomics 2012; 75: 3081-3097 [PMID: 22498886 DOI: 10.1016/j.jprot.2012.03.046]
24. Ebert MP, Meuer J, Wiemer JC, Schulz HU, Reymond MA, Traugott U, Malfertheiner P, Röcken C. Identification of gastric cancer patients by serum protein profiling. J Proteome R es 2004; 3: 1261-1266 [PMID: 15595736 DOI: 10.1021/pr049865s]
25. Liu C, Pan C, Liang Y. Screening and identification of serum proteomic biomarkers for gastric adenocarcinoma. Exp Ther Med 2012; 3: 1005-1009 [PMID: 22970007 DOI: 10.3892/etm.2012.515]
26. Li P, Zhang D, Guo C. Serum biomarker screening for the diagnosis of early gastric cancer using SELDI-TOF-MS. Mol Med Rep 2012; 5: 1531-1535 [PMID: 22427025 DOI: 10.3892/mmr.2012.834]
27. Poon TC, Sung JJ, Chow SM, Ng EK, Yu AC, Chu ES, Hui AM, Leung WK. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology 2006; 130: 1858-1864 [PMID: 16697748 DOI: 10.1053/j.gastro.2006.02.011]
28. Qian HG, Shen J, Ma H, Ma HC, Su YH, Hao CY, Xing BC, Huang XF, Shou CC. Preliminary study on proteomics of gastric carcinoma and its clinical significance. World J Gastroenterol 2005; 1 1: 6249-6253 [PMID: 16419150]
29. Liang Y, Fang M, Li J, Liu CB, Rudd JA, Kung HF, Yew DT. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Path ol 2006; 81: 176-180 [PMID: 16828742 DOI: 10.1016/j.yexmp.2006.04.008]
30. Fan NJ, Li K, Liu QY, Wang XL, Hu L, Li JT, Gao CF. Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c1 complex subunit 1 as serological diagnostic biomarkers of gastric cancer. Clin Biochem 2013; 46: 1578-1584 [PMID: 23747515 DOI: 10.1016/j.clinbiochem.2013.05.068]
31. Lu HB, Zhou JH, Ma YY, Lu HL, Tang YL, Zhang QY, Zhao CH. Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer. Jpn J Clin Oncol 2010; 40: 336-342 [PMID: 20089528 DOI: 10.1093/jjco/hyp175]
32. Su Y, Shen J, Qian H, Ma H, Ji J, Ma H, Ma L, Zhang W, Meng L, Li Z, Wu J, Jin G, Zhang J, Shou C. Diagnosis of gastric cancer usin g decision tree classification of mass spectral data. Cancer Sci 2007; 98: 37-43 [PMID: 17052262 DOI: 10.1111/j.1349-7006.2006.00339.x]
33. Wang P, Whiteaker JR, Paulovich AG. The evolving role of mass spectrometry in cancer biomarker discovery. Cancer Biol Ther 2009; 8: 1083-1094 [PMID: 19502776]
34. Yang J, Xiong X, Wang X, Guo B, He K, Huang C. Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer. Tumour Biol 2015; 36: 5109-5118 [PMID: 25677901 DOI: 10.1007/s13277-015-3163-2]
35. Ahn HS, Shin YS, Park PJ, Kang KN, Kim Y, Lee HJ, Yang HK, Kim CW. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer 2012; 106: 733-739 [PMID: 22240791 DOI: 10.1038/bjc.2011.592]
36. Surinova S, Schiess R, H üttenhain R, Cerciello F, Wollscheid B, Aebersold R. On the development of plasma protein biomarkers. J Proteome Res 2011; 10: 5-16 [PMID: 21142170 DOI: 10.1021/pr1008515]
37. Liu W, Liu B, Cai Q, Li J, Chen X, Zhu Z. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clin Chim Acta 2012; 413: 1098-1106 [PMID: 22446497 DOI: 10.1016/j.cca.2012.03.003]
38. Chong PK, Lee H, Loh MC, Choong LY, Lin Q, So JB, L im KH, Soo RA, Yong WP, Chan SP, Smoot DT, Ashktorab H, Yeoh KG, Lim YP. Upregulation of plasma C9 protein in gastric cancer patients. Proteomics 2010; 10: 3210-3221 [PMID: 20707004 DOI: 10.1002/p mic.201000127]
39. Ebert MP, Niemeyer D, Deininger SO, Wex T, Knippig C, Hoffmann J, Sauer J, Albrecht W, Malfertheiner P, Röcken C. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDITOF mass spectrometry. J Proteome Res 2006; 5: 2152-2158 [PMID: 16944926 DOI: 10.1021/pr060011c]
40. Zhang MH, Xu XH, Wang Y, Linq QX, Bi YT, Miao XJ, Ye CF, Gao SX, Gong CY, Xiang H, Dong MS. A prognostic biomarker for gastric cancer with lymph node metastases. Anat Rec (Hoboken) 2013; 296: 590-594 [PMID: 23382154 D OI: 10.1002/ar.22642]
41. Cohen M, Yossef R, Erez T, Kugel A, Welt M, Karpasas MM, Bones J, Rudd PM, Taieb J, Boissin H, Harats D, Noy K, Tekoah Y, Lichtenstein RG, Rubin E, P orgador A. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One 2011; 6: e14540 [PMID: 21267442 DOI: 10.1371/journal. pone.0014540 ]
42. Pitteri SJ, Kelly-Spratt KS, Gurley KE, Kennedy J, Buson TB, Chin A, Wang H, Zhang Q, Wong CH, Chodosh LA, Nelson PS, Hanash SM, Kemp CJ. Tumor microenvironment-derived proteins domina te the plasma proteome response during breast cancer induction and progression. Cancer Res 2011; 71: 5090-5100 [PMID: 21653680 DOI: 10.1158/0008-5472.CAN-11-0568]
43. Bones J, Byrne JC, O'D onoghue N, McManus C, Scaife C, Boissin H, Nastase A, Rudd PM. Glycomic and glycoproteomic analysis of serum from patients with stomach cancer reveals potential markers arising from host defense response mechanisms. J Proteom e Res 2011; 10: 1246-1265 [PMID: 21142185 DOI: 10.1021/pr101036b]
44. Gomes C, Almeida A, Ferreira JA, Silva L, Santos-Sousa H, Pintode-Sousa J, Santos LL, Amado F, Schwientek T, Levery SB, Mandel U, Clausen H, David L, Reis CA, Osó rio H. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J Proteome Res 2013; 12: 1454-1466 [PMID: 23312025 DOI: 10.1021/pr301112x]
45. Ozcan S, Barkauskas DA, Renee Ruhaak L, Torres J, Cooke CL, An HJ, Hua S, Williams CC, Dimapasoc LM, Han Kim J, Camorlinga-Ponce M, Rocke D, Lebrilla CB, Solnick JV. Serum glycan signatures of ga stric cancer. Cancer Prev Res (Phila) 2014; 7: 226-235 [PMID: 24327722 DOI: 10.1158/1940-6207. CAPR-13-0235]
46. Roy B, Chattopadhyay G, Mishra D, Das T, Chakraborty S, Maiti TK. On-chip lectin microarray for glycoprofiling of different gastritis types and gastric cancer. Biomicrofluidics 2014; 8: 034107 [PMID: 24959308 DOI: 10.1063/1.4882778]
47. Ruhaak LR, Barkauskas DA, Torres J, Cooke CL, Wu LD, Stroble C, Ozcan S, Williams CC, Camorlinga M, Rocke DM, Lebrilla CB, Solnick JV. The Serum Immunoglobulin G Glycosylation Signature of Gastric Cancer. EuPA Open Proteom 2015; 6: 1-9 [PMID: 25685702 DOI: 10.1016/j.euprot.2014.11.002]
48. Parker CE, Borchers CH. Mass spectrometry based biomarker discovery, verification, and validation-quality assurance and control of protein biomarker assays. Mol Oncol 2014; 8: 840-858 [PMID: 24713096 DOI: 10.1016/j.molonc.2014.03.006]
49. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570 [PMID: 21436444 DOI: 10.1126/science.1203486]
50. Chapman C, Murray A, Chakraba rti J, Thorpe A, Woolston C, Sahin U, Barnes A, Robertson J. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18: 868-873 [PMID: 17347129 DOI: 10.1093/annonc/mdm007 ]
51. Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-Associated antibodies for early detection of nonsmall cell lung cancer. J Thorac Oncol 2006; 1: 513-519 [PMID: 17409910]
52. Li Y, Karjalainen A, Koskinen H, Hemminki K, Vainio H, Shnaidman M, Ying Z, Pukkala E, Brandt-Rauf PW. p53 autoantibodies predict subsequent development of cancer. I nt J Cancer 2005; 114: 157-160 [PMID: 15523685 DOI: 10.1002/ijc.20715]
53. Preuss KD, Zwick C, Bormann C, Neumann F, Pfreundschuh M. Analysis of the B-cell repertoire against antigens expresse d by human neoplasms. Immunol Rev 2002; 188: 43-50 [PMID: 12445280]
54. Chen YT. Identification of human tumor antigens by serological expression cloning: an online review on SEREX. Cancer Immun 2004
55. Chapman CJ, Healey GF, Murray A, Boyle P, Robertson C, Peek LJ, Allen J, Thorpe AJ, Hamilton-Fairley G, Parsy-Kowalska CB, MacDonald IK, Jewell W, Maddison P, Robertson JF. EarlyCDT®-Lung test: improved clinical utility through additional autoantibody assays. Tumour Biol 2012; 33: 1319-1326 [PMID: 22492236 DOI: 10.1007/s13277-012-0379-2]
56. Zayakin P, Ancns G, Silia K, Meistere I, Kalnia Z, Andrejeva D, Endzeli͉ E, Ivanova L, Pismennaja A, Ruskule A, Donia S, Wex T, Malfertheiner P, Leja M, Lin A. Tumor-Associated autoantibody signature for the early detection of gastric cancer. Int J Cancer 2013; 132: 137-147 [PMID: 22684876 DOI: 10.1002/ijc.27667]
57. Gnjatic S,Ritter E,Büchler MW,Giese NA,Brors B,Frei C,Murray A,Halama N,Zör nig I,Chen YT,Andrews C,Ritter G,Old LJ,Odunsi K,Jäger D. Seromic profiling of ovarian and pancreatic cancer Proc Natl Acad Sci USA 2010 107 5088-5093 PMID: 20194765 DOI: 10.1073/pnas.0914213107]
58. Werner S, Chen H, Tao S, Brenner H. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer 2015; 136: 2243-2252 [PMID: 24615018 DOI: 10.1002/i jc.28807]
59. Fujiwara S, Wada H, Kawada J, Kawabata R, Takahashi T, Fujita J, Hirao T, Shibata K, Makari Y, Iijima S, Nishikawa H, Jungbluth AA, Nakamura Y, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y. NYESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer 2013; 108: 1119-1125 [PMID: 23403818 DOI: 10.1038/bjc.201 3.51]
60. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, deKernion JB, Belldegrun AS. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer 2005; 114: 268-273 [PMID: 15540228 DOI: 10.1002/ijc.20716]
61. Kurtenkov O, Klaamas K, Mensdorff-P ouilly S, Miljukhina L, Shljapnikova L, Chuzmarov V. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 2007; 46: 316-323 [ PMID: 17450466 DOI: 10.1080/02841860601055441]
62. Zhang JY, Chan EK, Peng XX, Lu M, Wang X, Mueller F, Tan EM. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. C lin Immunol 2001; 100: 149-156 [PMID: 11465943 DOI: 10.1006/clim.2001.5048]
63. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in c ancer using panel of recombinant tumor-Associated antigens. Cancer Epidemiol Biomarkers Prev 2003; 12: 136-143 [PMID: 12582023]
64. Megliorino R, Shi FD, Peng XX, Wang X, Chan EK, Tan EM, Zhang JY. Autoimmune response to anti-Apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 2005; 29: 241-248 [PMID: 15896923 DOI: 10.1016/j.cdp.2005.03.002]
65. Meistere I, Kalnina, Z, Silina, K, Line, A. Cancer-Associated Autoantibodies as Biomarkers for Early Detection and Prognosis is Cancer: An Update. Curr Canc Ther Rev 2013; 9: 10 [DOI: 10.2174/157339470904140418093612]
66. Preiss S, Kammertoens T, Lampert C, Willimsky G, Blankenstein T. Tumor-induced antibodies resemble the response to tissue damage. Int J Cancer 2005; 1 15: 456-462 [PMID: 15700321 DOI: 10.1002/ijc.20914]
67. Ludewig B, Krebs P, Metters H, Tatzel J, Türeci O, Sahin U. Molecular characterization of virus-induced autoantibody responses. J Exp Me d 2004; 200: 637-646 [PMID: 15353556 DOI: 10.1084/jem.20040358]
68. Zhou SL, Ku JW, Fan ZM, Yue WB, Du F, Zhou YF, Liu YL, Li Y, Tang S, Hu YL, Hu XP, Hou ZC, Liu J, Liu Y, Feng XS, Wang LD. Detection of autoantibodies to a panel of tumor-Associated antigens for the diagnosis values of gastric cardia adenocarcinoma. Dis Esophagus 2015; 28: 371-379 [PMID: 24612004 DOI: 10.111 1/dote.12206]
69. Shiota G, Ishida M, Noguchi N, Takano Y, Oyama K, Okubo M, Katayama S, Harada K, Hori K, Ashida K, Kishimoto Y, Hosoda A, Suou T, Ito H, Kawasaki H. Clinica l significance of serum P53 antibody in patients with gastric cancer. Res Commun Mol Pathol Pharmacol 1998; 99: 41-51 [PMID: 9523354]
70. Qiu LL, Hua PY, Ye LL , Wang YC, Qiu T, Bao HZ, Wang L. The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect Prev 2007; 31: 45-49 [PMID: 17292563 DOI: 10.1016/j.cdp.2006.12.005]
71. Reuschenbach M, von Knebel Doeberitz M, Wentzensen N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 2009; 58: 1535-1544 [PMID: 19562338 DOI: 10.1007/s00262-009-0733-4]
72. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, Correa I, Roberts L, Beddowes E, Koers A, Hobbs C, Ferreira S, Geh JL, Healy C, Harries M, Acland KM, Blower PJ, Mitchell T, Fear DJ, Spicer JF, Lacy KE, Nestle FO, Karagiannis SN. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest 2013; 1 23: 1457-1474 [PMID: 23454746 DOI: 10.1172/JCI65579]
73. Mandel P, Metais P. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948; 142: 241-243 [PMID: 18875018]
74. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437 [PMID: 21562580 DOI: 10.1038/nrc3066]
75. Su Z, Yang Z, Xu Y, Chen Y, Yu Q. MicroRNAs in apoptosis, autophagy and necroptosis. Oncotarget 2015; 6: 8474-8490 [PMID: 25893379]
76. Ivanov A, Pawlikowski J, Manoharan I, van Tuyn J, Nelson DM, Rai TS, Shah PP, Hewitt G, Korolchuk VI, Passos JF, Wu H, Berger SL, Adams PD. Lysosome-mediated processing of chromatin in senescence. J Cell Biol 2013; 202: 129-143 [PMID: 23816621 DOI: 10.1083/jcb.201212110]
77. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange be tween cells. Nat Cell Biol 2007; 9: 654-659 [PMID: 17486113 DOI: 10.1038/ncb1596]
78. Gy örgy B,Szabó TG,Pásztói M,Pál Z,Misják P,Aradi B,László V,Pállinger E,Pap E,,Kittel A,Nagy G,Falus A,Buzás EI. Membrane vesicles, current state-of-the-Art: emerging role of extracellular vesicles Cell Mol Life Sci 2011 68 2667-2688 PMID: 21560073 DOI: 10.1007/s00018-011-0689-3]
79. Sadovska L, Bajo CS, Kalnia Z, Lin A. Biodistribution, Uptake and Effects Caused by Cancer-derived Extracellular Vesicles. JCB 2015; 4: 1-15 [DOI: 10.5772/60522]
80. Zandberga E, Kozirovskis V, ?bols A, Andrjeva D, Purkalne G, Lin A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer 2013; 52: 356-369 [PMID: 23404859 DOI: 10.1002/gcc.22032]
81. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R. DNA fragments in the blood plasma of cancer patients: quantitations and evidence fo r their origin from apoptotic and necrotic cells. Cancer Res 2001; 61: 1659-1665 [PMID: 11245480]
82. Wang BG, Huang HY, Chen YC, Bristow RE, Kassauei K, Cheng CC, Roden R, Sokoll LJ, Chan DW, Shih IeM. Increased plasma DNA integrity in cancer patients. Cancer Res 2003; 63: 3966-3968 [PMID: 12873992]
83. Umetani N, Giuliano AE, Hiramatsu SH, Amersi F, Nakag awa T, Martino S, Hoon DS. Prediction of breast tumor progression by integrity of free circulating DNA in serum. J Clin Oncol 2006; 24: 4270-4276 [PMID: 16963729 DOI: 10.1200/JCO.2006.05.9493]
84. Umetani N, Kim J, Hiramatsu S, Reber HA, Hines OJ, Bilchik AJ, Hoon DS. Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem 2006; 52: 1062-1069 [PMID: 16723681 DOI: 10.1373/clinchem.2006.068577]
85. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, P eterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M. Circulating microRNAs as stable blood-b ased markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-10518 [PMID: 18663219 DOI: 10.1073/pnas.0804549105]
86. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of micr oRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One 2012; 7: e30679 [PMID: 22427800 DOI: 10.1371/journal.pone.0030679]
87. Cheng L, Sharples RA, Scicluna BJ, Hill AF. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 2014; 3: [PMID: 24683445 DOI: 10.3402/jev.v3.23743]
88. Arroyo JD, C hevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independ ent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108: 5003-5008 [PMID: 21383194 DOI: 10.1073/pnas.1019055108]
89. Chevillet JR, Kang Q, Ruf IK, Briggs HA, Vojtech LN, Hughes SM , Cheng HH, Arroyo JD, Meredith EK, Gallichotte EN, Pogosova-Agadjanyan EL, Morrissey C, Stirewalt DL, Hladik F, Yu EY, Higano CS, Tewari M. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA 2014; 111: 14888-14893 [PMID: 25267620 DOI: 10.1073/pnas.1408301111]
90. Sai S, Ichikawa D, Tomita H, Ikoma D, Tani N, Ikoma H, Kikuchi S, Fujiwa ra H, Ueda Y, Otsuji E. Quantification of plasma cellfree DNA in patients with gastric cancer. Anticancer Res 2007; 27: 2747-2751 [PMID: 17695442]
91. Park JL, Kim HJ, Choi BY, Lee HC , Jang HR, Song KS, Noh SM, Kim SY, Han DS, Kim YS. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett 2012; 3: 921-926 [PMID: 22741019 DOI: 10.3892/ol.2012.592]
92. Kim K, Shin DG, Park MK, Baik SH, Kim TH, Kim S, Lee S. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res 2014; 86: 136-142 [PMID: 24761422 DOI: 10.4174/astr.2014.86.3.136]
93. Kolesnikova EV, Tamkovich SN, Bryzgunova OE, Shelestyuk PI, Permyakova VI, Vlassov VV, Tuzikov AS, Laktionov PP, Rykova EY. Circulating DNA in the blood of gastric cancer patients. Ann N Y Acad Sci 2008; 1137: 226-231 [PMID: 18837952 DOI: 10.1196/annals.1448.009]
94. Coimbra S, Catarino C, Costa E, Oliveira H, Figueiredo A, Rocha-Pereira P, Santos-Silva A. Circulating cell-free DNA levels in Portuguese patients with psoriasis vulgaris according to severity and therap y. Br J Dermatol 2014; 170: 939-942 [PMID: 24245854 DOI: 10.1111/bjd.12738]
95. Outinen TK, Kuparinen T, JylhäväJ, Leppänen S, Mustonen J, MäkeläS, Pörsti I, Syrjänen J, Vahe ri A, Hurme M. Plasma cellfree DNA levels are elevated in acute Puumala hantavirus infection. PLoS One 2012; 7: e31455 [PMID: 22347483 DOI: 10.1371/journal. pone.0031455]
96. JylhäväJ, Lehtimäki T, Jula A, Moilanen L, Kesäniemi YA, Nieminen MS, Kähönen M, Hurme M. Circulating cell-free DNA is associated with cardiometabolic risk factors: the Health 2000 Survey. Atherosclerosis 2014; 233: 268-271 [PMID: 24529155 DOI: 10.1016/j.atherosclerosis.2013.12.022]
97. Breitbach S, Tug S, Simon P. Circulating cell-free DNA: an upcoming molecular marker in exercise physiology. Sports Med 2012; 42: 565-586 [PMID: 22694348 DOI: 10.2165/11631380-000000000-00000]
98. Hamakawa T, Kukita Y, Kurokawa Y, Miyazaki Y, Takahashi T, Yamasaki M, Miyata H, Nakajima K, Taniguchi K, Takiguchi S, Mori M, Doki Y, Kato K. Monitoring gastric cancer progression wit h circulating tumour DNA. Br J Cancer 2015; 112: 352-356 [PMID: 25490524 DOI: 10.1038/bjc.2014.609]
99. Park KU, Lee HE, Park do J, Jung EJ, Song J, Kim HH, Choe G, Kim WH, Lee HS. MY C quantitation in cell-free plasma DNA by real-time PCR for gastric cancer diagnosis. Clin Chem Lab Med 2009; 47: 530-536 [PMID: 19302034 DOI: 10.1515/CCLM.2009.126]
100. Shoda K, Masuda K, Ichi kawa D, Arita T, Miyakami Y, Watanabe M, Konishi H, Imoto I, Otsuji E. HER2 amplification detected in the circulating DNA of patients with gastric cancer: a retrospective pilot study. Gastric Cancer 2015; 18: 698-710 [PMID: 25322965 DOI: 10.1007/s10120-014-0432-5]
101. Lee HE, Park KU, Yoo SB, Nam SK, Park do J, Kim HH, Lee HS. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. Eur J Cancer 2013; 49: 1448-1457 [PMID: 23146959 DOI: 10.1016/j.ejca.2012.10.018]
102. Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, España P, Bonilla F. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res 1999; 59: 3251-3256 [PMID: 10397273]
103. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67-70 [PMID: 9892187]
104. Lee TL, Leung WK, Chan MW, Ng EK, Tong JH, Lo KW, Chung SC, Sung JJ, To KF. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res 2002; 8: 1761-1766 [PMID: 12060614]
105. Tsujiura M, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Otsuji E. Liquid biopsy of gastric cancer patien ts: circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2014; 20: 3265-3286 [PMID: 24696609 DOI: 10.3748/wjg.v20.i12.3265]
106. Toiyama Y, Okugawa Y, Goel A. DNA methylation and microRNA biomarkers for noninvasive detection of gastric and colorectal cancer. Biochem Biophys Res Commun 2014; 455: 43-57 [PMID: 25128828 DOI: 10.1016/j.bbrc.2014.08.001]
107. Bernal C, Aguayo F, Villarroel C, Vargas M, Díaz I, Ossandon FJ, Santibáñez E, Palma M, Aravena E, Barrientos C, Corvalan AH. Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res 2 008; 14: 6264-6269 [PMID: 18829507 DOI: 10.1158/1078-0432.CCR-07-4522]
108. Ling ZQ, Lv P, Lu XX, Yu JL, Han J, Ying LS, Zhu X, Zhu WY, Fang XH, Wang S, Wu YC. C irculating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. PLoS One 2013; 8: e67195 [PMID: 23826230 DOI: 10.1371/journal.pone.0067195]
109. Zheng Y, Chen L, Li J, Yu B, Su L, Che n X, Yu Y, Yan M, Liu B, Zhu Z. Hypermethylated DNA as potential biomarkers for gastric cancer diagnosis. Clin Biochem 2011; 44: 1405-1411 [PMID: 21945024 DOI: 10.1016/j.clinbiochem.2011.09.006]
110. Ooki A, Yamashita K, Yamaguchi K, Mondal A, Nishimiya H, Watanabe M. DNA damage-inducible gene, reprimo functions as a tumor suppressor and is suppressed by promoter methylation in gastric cancer. Mol Cancer Res 2013; 11: 1362-1374 [PMID: 23982217 DOI: 10.1158/1541-7786.MCR-13-0091]
111. Rand K, Qu W, Ho T, C lark SJ, Molloy P. Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods 2002; 27: 114-120 [PMID: 12095268]
112. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A. Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res 2008; 36: e42 [PMID: 18344521 DOI: 10.1093/nar/gkn113]
113. Lim AM, Candiloro IL, Wong N, Collins M, Do H, Takano EA, Angel C, Young RJ, Corry J, Wiesenfeld D, Kleid S, Sigston E, Lyons B, Rischin D, Solomon B, Dobrovic A. Quantitative methodology is critical for assessing DNA methylation and impacts on correlation with patient outcome. Clin Epigenetics 2014; 6: 22 [PMID: 25859283 DOI: 10.1186/1868-7083-6-22]
114. Li M, Chen WD, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S, Levin B, Juhl H, Arber N, Moinova H, Durkee K, Schmidt K, He Y, Diehl F, Velculescu VE, Zhou S, Diaz LA, Kinzler KW, Markowitz SD, Vogelstein B. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009; 27: 858-863 [PMID: 196 84580 DOI: 10.1038/nbt.1559]
115. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006 [PMID: 18766170 DOI: 10.1038/cr.2008.282]
116. Wang R, Wen H, Xu Y, Chen Q, Luo Y, Lin Y, Luo Y, Xu A. Circulating microRNAs as a novel cl ass of diagnostic biomarkers in gastrointestinal tumors detection: a meta-Analysis based on 42 articles. PLoS One 2014; 9: e113401 [PMID: 25406082 DOI: 10.1371/journal.pone.0113401]
117. Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-1179 [PMID: 20234369 DOI: 10.1038/sj.bjc.6605608]
118. Palma J, Yaddanapudi SC, Pigati L, Havens MA, Jeong S, Weiner GA, Weimer KM, Stern B, Hastings ML, Duelli DM. MicroR NAs are exported from malignant cells in customized particles. Nucleic Acids Res 2012; 40: 9125-9138 [PMID: 22772984 DOI: 10.1093/nar/gks656]
119. Konishi H, Ichikawa D, Komatsu S, Shiozaki A, Tsujiura M, Takeshita H, Morimura R, Nagata H, Arita T, Kawaguchi T, Hirashima S, Fujiwara H, Okamoto K, Otsuji E. Detection of gastric cancer-Associated microRNAs on microRNA microarray comparing pre-And post-op erative plasma. Br J Cancer 2012; 106: 740-747 [PMID: 22262318 DOI: 10.1038/bjc.2011.588]
120. Zhu C, Ren C, Han J, Ding Y, Du J, Dai N, Dai J, Ma H, Hu Z, Shen H , Xu Y, Jin G. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer 2014; 110: 2291-2299 [PMID: 24595006 DOI: 10.1038/bjc.2014.119]
121. Li BS,Zhao YL,Guo G,Li W,Zhu ED,Luo X,Mao XH,Zou QM,Yu PW,Zuo QF,Li N,Tang B,Liu KY,Xiao B. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomark ers for gastric cancer detection. PLoS One 2012; 7: e41629 PMID: 22860003 10.1371/journal.pone.0041629]
122. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, Ma Y, Xiao H. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 2012; 316: 196-203 [PMID: 22169097 DOI: 10.1016/j.canlet.2011.10.034]
123. Su ZX, Zhao J, Rong ZH, Wu YG, Geng WM, Qin CK. Diagnostic and prognostic value of circulating miR-18a in the plasma of patients with gastric cancer. Tumour Biol 2014; 35: 12119-12125 [PMID: 25416437 DOI: 10.1007/s13277-014-2516-6]
124. Song MY, Pan KF, Su HJ, Zhang L, Ma JL, Li JY, Yuasa Y, Kang D, Kim YS, You WC. Identification of serum microRNAs as novel non-invasive biomarkers for early det ection of gastric cancer. PLoS One 2012; 7: e33608 [PMID: 22432036 DOI: 10.1371/journal. pone.0033608]
125. Kang Y, Zhang J, Sun P, Shang J. Circulating cell-free human telomerase reverse transcript ase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer. Int J Clin Oncol 2013; 18: 478-486 [PMID: 22527847 DOI: 10.1007/s10147-012-0405-9]
126. Qi P, Du X. The long non-coding RNAs, a new cancer diagnostic and therapeutic gold mine. Mod Pathol 2013; 26: 155-165 [PMID: 22996375 DOI: 10.1038/modpathol.2012.160]
127. Peng L, Yuan XQ, Li GC. The emerging landscape of circular RNA ciRS-7 in cancer (Review). Oncol Rep 2015; 33: 2669-2674 [PMID: 25873049 DOI: 10.3892/or.2015.3904]
128. Arita T, Ichikawa D, Konishi H, Komatsu S, Shiozaki A, Shoda K, Kawaguchi T, Hirajima S, Nagata H, Kubota T, Fujiwara H, Okamoto K, Otsuji E. Circulating long non-coding RNAs in plasma of patients with gastric canc er. Anticancer Res 2013; 33: 3185-3193 [PMID: 23898077]
129. Liu Z, Shao Y, Tan L, Shi H, Chen S, Guo J. Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumour Biol 2014; 35: 9613-9617 [PMID: 24961353 DOI: 10.1007/s13277-014-2259-4]
130. Zeng X, Shi H, Wang J, Cui S, Tang H, Zhang X. Long noncoding RNA aberrant expressio n profiles after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of AGC ascertained by microarray analysis. Tumour Biol 2015; 36: 5021-5029 [PMID: 25652469 DOI: 10.1007/s13277-015-3153-4]
131. Li Q, Shao Y, Zhang X, Zheng T, Miao M, Qin L, Wang B, Ye G, Xiao B, Guo J. Plasma long noncoding RNA protected by exosomes as a potential stable biomarker for gastric cancer. Tumour Biol 20 15; 36: 2007-2012 [PMID: 25391424 DOI: 10.1007/s13277-014-2807-y]
132. Li P, Chen S, Chen H, Mo X, Li T, Shao Y, Xiao B, Guo J. Using circular RNA as a novel type of biomarker in the screening of gastric cancer. Clin Chim Acta 2015; 444: 132-136 [PMID: 25689795 DOI: 10.1016/j.cca.2015.02.018]
133. Xiang M, Zeng Y, Yang R, Xu H, Chen Z, Zhong J, Xie H, Xu Y, Zeng X. U6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun 2014; 454: 210-214 [PMID: 25450382 DOI: 10.1016/j.bbrc.2014.10.064]
134. Keller A, Leidinger P, Gislefoss R, Haugen A, Langseth H, Staehler P, Lenhof HP, Meese E. Stable serum miRNA profiles as potential tool for non-invasive lung cancer diagnosis. RNA Biol 2011; 8 : 506-516 [PMID: 21558792]
135. Kirschner MB, Kao SC, Edelman JJ, Armstrong NJ, Vallely MP, van Zandwijk N, Reid G. Haemolysis during sample preparation alters microRNA content of plasma. PLoS One 2011; 6: e24145 [PMID: 21909417 DOI: 10.1371/journal.pone.0024145]
136. Hiraiwa K, Takeuchi H, Hasegawa H, Saikawa Y, Suda K, Ando T, Kumagai K, Irino T, Yoshikawa T, Matsuda S, Kitajima M, Kitagawa Y. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol 2008; 15: 3092-3100 [PMID: 18766405 DOI: 10.1245/s10434-008-0122-9]
137. Toss A, Mu Z, Fernandez S, Cristofanilli M. CTC enumeration and characterization: moving toward personalized medicine. Ann Transl Med 2014; 2: 108 [PMID: 25489582 DOI: 10.3978/j.issn.2305-5839 .2 014.09.06]
138. Moreno JG, O'Hara SM, Gross S, Doyle G, Fritsche H, Gomella LG, Terstappen LW. Changes in circulating carcinoma cells in patients with metastatic prostate cancer correlate with disea se status. Urology 2001; 58: 386-392 [PMID: 11549486]
139. Kolostova K, Matkowski R, Gurlich R, Grabowski K, Soter K, Lischke R, Schutzner J, Bobek V. Detection and cultivatio n of circulating tumor cells in gastric cancer. Cytotechnology 2015; Epub ahead of print [PMID: 25862542 DOI: 10.1007/s10616-015-9866-9]
140. Uenosono Y, Arigami T, Kozono T, Yanagita S, Hagihara T, Haraguchi N, Matsushita D, Hirata M, Arima H, Funasako Y, Kijima Y, Nakajo A, Okumura H, Ishigami S, Hokita S, Ueno S, Natsugoe S. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer 2013; 119: 3984-3991 [PMID: 23963829 DOI: 10.1002/cncr.28309]
141. Katsuda T , Kosaka N, Ochiya T. The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers. Proteomics 2014; 14: 412-425 [PMID: 24339442 DOI: 10.1002/pmic.201300389]
142. Thakur BK,Zhang H,Becker A,Matei I,Huang Y,Costa-Silva B,Zheng Y,Hoshino A,Brazier H,Xiang J,Williams C,Rodriguez-Barrueco R,Silva JM,Zhang W,Hearn S,Elemento O,Pa knejad N,Manova-Todorova K,Welte K,Bromberg J,Peinado H,Lyden D. Double-stranded DNA in exosomes: a novel biomarker in cancer detection Cell Res 2014 24 766-769 PMID: 24710597 DOI: 10.1038/cr. 2014.44]
143. Fais S, Logozzi M, Lugini L, Federici C, Azzarito T, Zarovni N, Chiesi A. Exosomes: the ideal nanovectors for biodelivery. Biol Chem 2013; 394: 1-15 [PMID: 23241589 DOI: 10.1515/hsz-2012-0236]
144. Zocco D, Ferruzzi P, Cappello F, Kuo WP, Fais S. Extracellular vesicles as shuttles of tumor biomarkers and anti-tumor drugs. Front Oncol 2014; 4: 267 [PMID: 25340037 DOI: 10.3389/fonc.2014.00267]
145. Baran J, Baj-Krzyworzeka M, Weglarczyk K, Szatanek R, Zembala M, Barbasz J, Czupryna A, Szczepanik A, Zembala M. Circulating t umour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother 2010; 59: 841-850 [PMID: 20043223 DOI: 10.1007/s00262-009-0808-2]
146. Schneider J, Schulze G. C omparison of tumor M2-pyruvate kinase (tumor M2-PK), carcinoembryonic antigen (CEA), carbohydrate antigens CA 19-9 and CA 72-4 in the diagnosis of gastrointestinal cancer. Anticancer Res 2003; 23: 5089-5093 [PMID: 14981971]
147. Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H, Haglund C. CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res 2002; 22: 2311-2316 [PMID: 12174919]
148. Yang J, Song YC, Dang CX, Song TS, Liu ZG, Guo YM, Li ZF, Huang C. Serum peptidome profiling in patients with gastric cancer. Clin Exp Med 2012; 12: 79-87 [PMID: 21739109 DOI: 10.1007/s10238-011-0149-2]
149. Xu QW, Zhao W, Wang Y, Sartor MA, Han DM, Deng J, Ponnala R, Yang JY, Zhang QY, Liao GQ, Qu YM, Li L, Liu FF, Zhao H M, Yin YH, Chen WF, Zhang Y, Wang XS. An integrated genomewide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res 2012; 72: 6351-6361 [PMID: 23 135912 DOI: 10.1158/0008-5472. CAN-12-1656]
150. Looi K, Megliorino R, Shi FD, Peng XX, Chen Y, Zhang JY. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 2006; 16: 1105-1110 [PMID: 17016600]
151. Koziol JA, Zhang JY, Casiano CA, Peng XX, Shi FD, Feng AC, Chan EK, Tan EM. Recursive partitioning as an approach to selection o f immune markers for tumor diagnosis. Clin Cancer Res 2003; 9: 5120-5126 [PMID: 14613989]
152. Sakakura C, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, Ida H, Yazumi S, Otsuji E, Chiba T, Ito K, Ito Y. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res 2009; 29: 2619-2625 [PMID: 19596937]
153. Ng EK, Leung CP, Shin VY, Wong CL, Ma ES, Jin HC, Chu KM, Kwong A. Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One 2011; 6: e22233 [PMID: 21789241 DOI: 10.1371/journal.pone.0022233]
154. Chen L, Su L, Li J, Zheng Y, Yu B, Yu Y, Yan M, Gu Q, Zhu Z, Liu B. Hypermethylated FAM5C and MYLK in serum as diagnosis and pre-warning markers for gastric cancer. Dis Markers 2012; 32: 195-202 [PMID: 22377736 DOI: 10.3233/DMA-2011-0877]
155. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, Yin J, Wang S, Zen K, Ba Y, Zhang CY. A five-microRNA signature identified fro m genomewide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2011; 47: 784-791 [PMID: 21112772 DOI: 10.1016/j.ejca.2010.10.025]
156. Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. Med Oncol 2013; 30: 452 [PMID: 23307259 DOI: 10.1007/s12032-012-0452-0]
157. Wang H, Wang L, Wu Z, Sun R, Jin H, Ma J, Liu L, Ling R, Yi J, Wang L, Bian J, Chen J, Li N, Yuan S, Yun J. Three dysregulated microRNAs in serum as novel biomarkers for gastric cancer screening. Med Oncol 2014; 31: 298 [PMID: 25367852 DOI: 10.1007/s12032-014-0298-8]
158. Fu Z, Qian F, Yang X, Jiang H, Chen Y, Liu S. Circulating miR-222 in p lasma and its potential diagnostic and prognostic value in gastric cancer. Med Oncol 2014; 31: 164 [PMID: 25129310 DOI: 10.1007/s12032-014-0164-8]
159. Tsujiura M, Komatsu S, Ichikawa D, Shio zaki A, Konishi H, Takeshita H, Moriumura R, Nagata H, Kawaguchi T, Hirajima S, Arita T, Fujiwara H, Okamoto K, Otsuji E. Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. Gastric Cancer 2015; 18: 271-279 [PMID: 24626859 DOI: 10.1007/s10120-014-0363-1]
160. Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke KD, Stein U. Circulating Metastasis Associated in Colon Cancer 1 transcripts in gastric cancer patient plasma as diagnostic and prognostic biomarker. World J Gastroenterol 2015; 21: 333-341 [PMID: 25574109 DOI: 10.3748/wjg.v21.i1.333]